335 results on '"Gensler, Lianne S."'
Search Results
2. A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination
- Author
-
Greene, Sarah E, Huang, Yuefang, Kim, Wooseob, Liebeskind, Mariel J, Chandrasekaran, Vinay, Liu, Zhuoming, Deepak, Parakkal, Paley, Michael A, Lew, Daphne, Yang, Monica, Matloubian, Mehrdad, Gensler, Lianne S, Nakamura, Mary C, O'Hallaran, Jane A, Presti, Rachel M, Whelan, Sean PJ, Buchser, William J, Kim, Alfred HJ, and Weil, Gary J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Vaccine Related ,Emerging Infectious Diseases ,Biodefense ,Biotechnology ,Infectious Diseases ,Clinical Research ,Immunization ,Prevention ,Infection ,Good Health and Well Being ,SARS-COV-2 ,Antibody test ,Vaccination ,Immunocompromise - Abstract
ObjectiveLateral flow assays (LFA) are sensitive for detecting antibodies to SARS-CoV-2 proteins within weeks after infection. This study tested samples from immunocompetent adults, and those receiving treatments for chronic inflammatory diseases (CID), before and after mRNA SARS-CoV-2 vaccination.MethodsWe compared results obtained with the COVIBLOCK Covid-19 LFA to those obtained by anti-spike (S) ELISA.ResultsThe LFA detected anti-S antibodies in 29 of 29 (100%) of the immunocompetent and 110 of 126 (87.3%) of the CID participants after vaccination. Semiquantitative LFA scores were statistically significantly lower in samples from immunosuppressed participants, and were significantly correlated with anti-S antibody levels measured by ELISA.ConclusionsThis simple LFA test is a practical alternative to laboratory-based assays for detecting anti-S antibodies after infection or vaccination. This type of test may be most useful for testing people in outpatient or resource-limited settings.
- Published
- 2023
3. Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis
- Author
-
Stovall, Rachael, van der Horst-Bruinsma, Irene E, Liu, Shao-Hsien, Rusman, Tamara, and Gensler, Lianne S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Arthritis ,Autoimmune Disease ,2.1 Biological and endogenous factors ,Aetiology ,Musculoskeletal ,Male ,Female ,Humans ,Spondylarthritis ,Prevalence ,Sex Characteristics ,Axial Spondyloarthritis ,Spondylitis ,Ankylosing ,Clinical sciences - Abstract
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that predominantly affects the axial skeleton, although it can affect peripheral joints, and extra-musculoskeletal manifestations also occur. Historically, axSpA was thought to be a disease predominantly seen in men, although with the advent of magnetic resonance imaging techniques and advances in research, this dogma has been challenged and refuted. Sex and gender are different concepts, and both can have a role in disease. In axSpA, consideration of the influence of sex and gender on the disease phenotype is necessary to predict outcomes and to enable the development of therapeutic approaches that are best suited to individual patients.
- Published
- 2022
4. The association of TNF inhibitor use with incident cardiovascular events in radiographic axial spondyloarthritis
- Author
-
Liew, Jean W., Treu, Timothy, Park, Yojin, Ferguson, Jacqueline M., Rosser, Morgan A., Ho, Yuk-Lam, Gagnon, David R., Stovall, Rachael, Monach, Paul, Heckbert, Susan R., Gensler, Lianne S., Liao, Katherine P., and Dubreuil, Maureen
- Published
- 2024
- Full Text
- View/download PDF
5. Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis
- Author
-
Braun, Juergen, Blanco, Ricardo, Marzo-Ortega, Helena, Gensler, Lianne S., Van den Bosch, Filip, Hall, Stephen, Kameda, Hideto, Poddubnyy, Denis, van de Sande, Marleen, van der Heijde, Désirée, Zhuang, Tingting, Stefanska, Anna, Readie, Aimee, Richards, Hanno B., and Deodhar, Atul
- Published
- 2023
- Full Text
- View/download PDF
6. Combined Single Cell Transcriptome and Surface Epitope Profiling Identifies Potential Biomarkers of Psoriatic Arthritis and Facilitates Diagnosis via Machine Learning
- Author
-
Liu, Jared, Kumar, Sugandh, Hong, Julie, Huang, Zhi-Ming, Paez, Diana, Castillo, Maria, Calvo, Maria, Chang, Hsin-Wen, Cummins, Daniel D, Chung, Mimi, Yeroushalmi, Samuel, Bartholomew, Erin, Hakimi, Marwa, Ye, Chun Jimmie, Bhutani, Tina, Matloubian, Mehrdad, Gensler, Lianne S, and Liao, Wilson
- Subjects
Biological Sciences ,Bioinformatics and Computational Biology ,Biomedical and Clinical Sciences ,Psoriasis ,Prevention ,Clinical Research ,Autoimmune Disease ,Rare Diseases ,Arthritis ,Genetics ,Aetiology ,2.1 Biological and endogenous factors ,Inflammatory and immune system ,Arthritis ,Psoriatic ,Biomarkers ,Epitopes ,Humans ,Machine Learning ,Transcriptome ,psoriatic arthritis ,psoriasis ,CITE-seq ,machine learning ,diagnostic test ,single cell ,Immunology ,Medical Microbiology ,Biochemistry and cell biology - Abstract
Early diagnosis of psoriatic arthritis (PSA) is important for successful therapeutic intervention but currently remains challenging due, in part, to the scarcity of non-invasive biomarkers. In this study, we performed single cell profiling of transcriptome and cell surface protein expression to compare the peripheral blood immunocyte populations of individuals with PSA, individuals with cutaneous psoriasis (PSO) alone, and healthy individuals. We identified genes and proteins differentially expressed between PSA, PSO, and healthy subjects across 30 immune cell types and observed that some cell types, as well as specific phenotypic subsets of cells, differed in abundance between these cohorts. Cell type-specific gene and protein expression differences between PSA, PSO, and healthy groups, along with 200 previously published genetic risk factors for PSA, were further used to perform machine learning classification, with the best models achieving AUROC ≥ 0.87 when either classifying subjects among the three groups or specifically distinguishing PSA from PSO. Our findings thus expand the repertoire of gene, protein, and cellular biomarkers relevant to PSA and demonstrate the utility of machine learning-based diagnostics for this disease.
- Published
- 2022
7. Single Cell Transcriptome and Surface Epitope Analysis of Ankylosing Spondylitis Facilitates Disease Classification by Machine Learning
- Author
-
Alber, Samuel, Kumar, Sugandh, Liu, Jared, Huang, Zhi-Ming, Paez, Diana, Hong, Julie, Chang, Hsin-Wen, Bhutani, Tina, Gensler, Lianne S, and Liao, Wilson
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Genetics ,Machine Learning and Artificial Intelligence ,Aetiology ,2.1 Biological and endogenous factors ,Inflammatory and immune system ,Epitopes ,Humans ,Leukocytes ,Mononuclear ,Machine Learning ,Spondylitis ,Ankylosing ,Transcriptome ,ankylosing spondylitis ,spondyloarthritis ,single cell sequencing ,CITE-seq ,genomics ,machine learning ,Medical Microbiology ,Biochemistry and cell biology - Abstract
Ankylosing spondylitis (AS) is an immune-mediated inflammatory disorder that primarily affects the axial skeleton, especially the sacroiliac joints and spine. This results in chronic back pain and, in extreme cases, ankylosis of the spine. Despite its debilitating effects, the pathogenesis of AS remains to be further elucidated. This study used single cell CITE-seq technology to analyze peripheral blood mononuclear cells (PBMCs) in AS and in healthy controls. We identified a number of molecular features associated with AS. CD52 was found to be overexpressed in both RNA and surface protein expression across several cell types in patients with AS. CD16+ monocytes overexpressed TNFSF10 and IL-18Rα in AS, while CD8+ TEM cells and natural killer cells overexpressed genes linked with cytotoxicity, including GZMH, GZMB, and NKG7. Tregs underexpressed CD39 in AS, suggesting reduced functionality. We identified an overrepresented NK cell subset in AS that overexpressed CD16, CD161, and CD38, as well as cytotoxic genes and pathways. Finally, we developed machine learning models derived from CITE-seq data for the classification of AS and achieved an Area Under the Receiver Operating Characteristic (AUROC) curve of > 0.95. In summary, CITE-seq identification of AS-associated genes and surface proteins in specific cell subsets informs our understanding of pathogenesis and potential new therapeutic targets, while providing new approaches for diagnosis via machine learning.
- Published
- 2022
8. Multimorbidity phenotypes in ankylosing spondylitis and their association with disease activity and functional impairment: Data from the prospective study of outcomes in ankylosing spondylitis cohort
- Author
-
Karmacharya, Paras, Crowson, Cynthia S., Lennon, Ryan J., Poudel, Dilli, Davis, John M, III, Ogdie, Alexis, Liew, Jean W., Ward, Michael M., Ishimori, Mariko, Weisman, Michael H., Brown, Matthew A., Rahbar, Mohammad H., Hwang, Mark C., Reveille, John D., and Gensler, Lianne S.
- Published
- 2024
- Full Text
- View/download PDF
9. A single center evaluation of applicant experiences in virtual interviews across eight internal medicine subspecialty fellowship programs.
- Author
-
Huppert, Laura A, Hsu, Gerald, Elnachef, Najwa, Flint, Lynn, Frank, James A, Gensler, Lianne S, Hsiao, Edward C, Khanna, Raman R, Qasim, Atif, Schwartz, Brian S, Widera, Eric, Zapata, Carly, and Babik, Jennifer M
- Subjects
Virtual interview ,covid-19 ,fellowship interviews ,remote interviews ,Public Health and Health Services ,Specialist Studies in Education - Abstract
Due to the COVID-19 pandemic, most graduate medical education (GME) training programs conducted virtual interviews for prospective trainees during the 2020-2021 application cycle. Many internal medicine (IM) subspecialty fellowship programs hosted virtual interviews for the first time with little published data to guide best practices.To evaluate how IM subspecialty fellowship applicants perceived the virtual interview day experience.We designed a 38-item questionnaire that was sent via email to applicants in eight IM subspecialty programs at a single tertiary academic medical center (University of California, San Francisco) from September-November, 2020.Seventy-five applicants completed the survey (75/244, 30.7%), including applicants from all eight fellowship programs. Most survey respondents agreed that the length of the virtual interview day (mean = 6.4 hours) was long enough to gather the information they needed (n = 65, 86.7%) and short enough to prevent fatigue (n = 55, 73.3%). Almost all survey respondents agreed that they could adequately assess the clinical experience (n = 71, 97.3%), research opportunities (n = 72, 98.6%), and program culture (n = 68, 93.2%). Of the respondents who attended a virtual educational conference, most agreed it helped to provide a sense of the program's educational culture (n = 20, 66.7%). Areas for improvement were identified, with some survey respondents reporting that the virtual interview day was too long (n = 11) or that they would have preferred to meet more fellows (n = 10).Survey respondents indicated that the virtual interview was an adequate format to learn about fellowship programs. These findings can inform future virtual interviews for GME training programs.
- Published
- 2021
10. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2
- Author
-
Deepak, Parakkal, Kim, Wooseob, Paley, Michael A, Yang, Monica, Carvidi, Alexander B, Demissie, Emanuel G, El-Qunni, Alia A, Haile, Alem, Huang, Katherine, Kinnett, Baylee, Liebeskind, Mariel J, Liu, Zhuoming, McMorrow, Lily E, Paez, Diana, Pawar, Niti, Perantie, Dana C, Schriefer, Rebecca E, Sides, Shannon E, Thapa, Mahima, Gergely, Maté, Abushamma, Suha, Akuse, Sewuese, Klebert, Michael, Mitchell, Lynne, Nix, Darren, Graf, Jonathan, Taylor, Kimberly E, Chahin, Salim, Ciorba, Matthew A, Katz, Patricia, Matloubian, Mehrdad, O'Halloran, Jane A, Presti, Rachel M, Wu, Gregory F, Whelan, Sean PJ, Buchser, William J, Gensler, Lianne S, Nakamura, Mary C, Ellebedy, Ali H, and Kim, Alfred HJ
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Prevention ,Rare Diseases ,Emerging Infectious Diseases ,Immunization ,Vaccine Related ,3.4 Vaccines ,Prevention of disease and conditions ,and promotion of well-being ,Good Health and Well Being ,Public Health and Health Services - Abstract
BackgroundPatients with chronic inflammatory disease (CID) treated with immunosuppressive medications have increased risk for severe COVID-19. Although mRNA-based SARS-CoV-2 vaccination provides protection in immunocompetent persons, immunogenicity in immunosuppressed patients with CID is unclear.ObjectiveTo determine the immunogenicity of mRNA-based SARS-CoV-2 vaccines in patients with CID.DesignProspective observational cohort study.SettingTwo U.S. CID referral centers.ParticipantsVolunteer sample of adults with confirmed CID eligible for early COVID-19 vaccination, including hospital employees of any age and patients older than 65 years. Immunocompetent participants were recruited separately from hospital employees. All participants received 2 doses of mRNA vaccine against SARS-CoV-2 between 10 December 2020 and 20 March 2021. Participants were assessed within 2 weeks before vaccination and 20 days after final vaccination.MeasurementsAnti-SARS-CoV-2 spike (S) IgG+ binding in all participants, and neutralizing antibody titers and circulating S-specific plasmablasts in a subset to assess humoral response after vaccination.ResultsMost of the 133 participants with CID (88.7%) and all 53 immunocompetent participants developed antibodies in response to mRNA-based SARS-CoV-2 vaccination, although some with CID developed numerically lower titers of anti-S IgG. Anti-S IgG antibody titers after vaccination were lower in participants with CID receiving glucocorticoids (n = 17) than in those not receiving them; the geometric mean of anti-S IgG antibodies was 357 (95% CI, 96 to 1324) for participants receiving prednisone versus 2190 (CI, 1598 to 3002) for those not receiving it. Anti-S IgG antibody titers were also lower in those receiving B-cell depletion therapy (BCDT) (n = 10). Measures of immunogenicity differed numerically between those who were and those who were not receiving antimetabolites (n = 48), tumor necrosis factor inhibitors (n = 39), and Janus kinase inhibitors (n = 11); however, 95% CIs were wide and overlapped. Neutralization titers seemed generally consistent with anti-S IgG results. Results were not adjusted for differences in baseline clinical factors, including other immunosuppressant therapies.LimitationsSmall sample that lacked demographic diversity, and residual confounding.ConclusionCompared with nonusers, patients with CID treated with glucocorticoids and BCDT seem to have lower SARS-CoV-2 vaccine-induced antibody responses. These preliminary findings require confirmation in a larger study.Primary funding sourceThe Leona M. and Harry B. Helmsley Charitable Trust, Marcus Program in Precision Medicine Innovation, National Center for Advancing Translational Sciences, and National Institute of Arthritis and Musculoskeletal and Skin Diseases.
- Published
- 2021
11. Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis
- Author
-
Liew, Jean W, Ward, Michael M, Reveille, John D, Weisman, Michael, Brown, Matthew A, Lee, MinJae, Rahbar, Mohammed, Heckbert, Susan R, and Gensler, Lianne S
- Subjects
Epidemiology ,Biomedical and Clinical Sciences ,Health Sciences ,Cardiovascular ,Prevention ,Hypertension ,Clinical Research ,Adult ,Anti-Inflammatory Agents ,Non-Steroidal ,Drug Administration Schedule ,Female ,Humans ,Incidence ,Longitudinal Studies ,Male ,Middle Aged ,Patient Reported Outcome Measures ,Prospective Studies ,Spondylitis ,Ankylosing ,Clinical Sciences ,Public Health and Health Services ,Psychology ,Clinical sciences ,Allied health and rehabilitation science - Abstract
ObjectiveNonsteroidal antiinflammatory drugs (NSAIDs) increase blood pressure and potentially cardiovascular burden, which may limit their use in ankylosing spondylitis (AS). Our objective was to determine the association of NSAID use with incident hypertension in a longitudinal AS cohort.MethodsAdults with AS were enrolled in a prospective cohort study of patient outcomes and examined every 4-6 months. Hypertension was defined by patient-reported hypertension; antihypertensive medication use; or, on 2 consecutive visits, systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg. Continuous NSAID use was dichotomized based on the validated NSAID index. We assessed the association of NSAID use as a time-varying exposure with the incidence of hypertension using Cox proportional hazards models.ResultsOf the 1,282 patients in the cohort, 628 patients without baseline hypertension had at least 1 year of follow-up and were included in the analysis. Of these, 72% were male, the mean age at baseline was 39 ± 13 years, and 200 patients used NSAIDs continuously. On follow-up, 129 developed incident hypertension. After controlling for other variables, continuous NSAID use was associated with a hazard ratio of 1.12 for incident hypertension (95% confidence interval 1.04-1.20), compared to noncontinuous or no use. The association did not differ in subgroups defined by age, body mass index, biologic use, or disease activity.ConclusionIn our prospective, longitudinal AS cohort, continuous NSAID use was associated with a 12% increased risk for the development of incident hypertension, as compared to noncontinuous or no NSAID use.
- Published
- 2020
12. Patient-reported Disease Activity in an Axial Spondyloarthritis Cohort during the COVID-19 Pandemic.
- Author
-
Liew, Jean W, Castillo, Maria, Zaccagnino, Ethan, Katz, Patricia, Haroon, Nigil, and Gensler, Lianne S
- Abstract
ObjectiveResponse to the coronavirus disease 2019 (COVID-19) pandemic has resulted in shelter-in-place orders and major changes to individuals' daily lives. The impact of such stressors on disease activity in individuals with axial spondyloarthritis (axSpA) is unclear. The aim of this study is to examine whether stress, anxiety, and depression are associated with patient-reported disease activity, after accounting for important factors.MethodsWe administered a survey to an axSpA cohort from a single center with well-defined demographic and disease characteristics. We included questions about job status changes, exercise, medication use, disease activity (by the Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]), and psychological factors (stress, depressive symptoms, and anxiety). Separate multivariable linear models examined the associations between perceived stress, anxiety, and depression with the BASDAI.ResultsAfter adjustment for potential confounders, those with higher levels of stress had a statistically significant 0.54-point higher BASDAI, on average, compared with those with lower levels of stress (95% confidence interval [CI]: 0.11, 0.97). Those with higher levels of anxiety also had a statistically significant higher BASDAI, on average, compared with those with lower levels of anxiety (β: 0.95, 95% CI: 0.18, 0.99). The association between depression and BASDAI was not statistically significant. We did not find differences in these associations among subgroups of age, job status, or county of residence.ConclusionIndividuals with axSpA with higher levels of stress and anxiety had significantly higher disease activity levels, although with a difference below clinical importance. Further planned studies will evaluate the trajectory of disease activity.
- Published
- 2020
13. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
- Author
-
Dougados, Maxime, Wei, James Cheng-Chung, Landewé, Robert, Sieper, Joachim, Baraliakos, Xenofon, Van den Bosch, Filip, Maksymowych, Walter P, Ermann, Joerg, Walsh, Jessica A, Tomita, Tetsuya, Deodhar, Atul, van der Heijde, Désirée, Li, Xiaoqi, Zhao, Fangyi, Bertram, Clinton C, Gallo, Gaia, Carlier, Hilde, and Gensler, Lianne S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adalimumab ,Antibodies ,Monoclonal ,Humanized ,Antirheumatic Agents ,Double-Blind Method ,Drug Substitution ,Female ,Humans ,Male ,Radiography ,Severity of Illness Index ,Spondylarthritis ,Time Factors ,Treatment Outcome ,Tumor Necrosis Factor Inhibitors ,COAST-V and COAST-W Study Groups ,DMARDs ,ankylosing spondylitis ,spondyloarthritis ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
OBJECTIVES:To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive (COAST-V) or tumour necrosis factor inhibitor (TNFi)-experienced (COAST-W). METHODS:Adults with active r-axSpA were randomised 1:1:1:1 (n=341) to 80 mg ixekizumab every 2 (IXE Q2W) or 4 weeks (IXE Q4W), placebo (PBO) or 40 mg adalimumab Q2W (ADA) in COAST-V and 1:1:1 (n=316) to IXE Q2W, IXE Q4W or PBO in COAST-W. At week 16, patients receiving ixekizumab continued their assigned treatment; patients receiving PBO or ADA were rerandomised 1:1 to IXE Q2W or IXE Q4W (PBO/IXE, ADA/IXE) through week 52. RESULTS:In COAST-V, Assessment of SpondyloArthritis international Society 40 (ASAS40) responses rates (intent-to-treat population, non-responder imputation) at weeks 16 and 52 were 48% and 53% (IXE Q4W); 52% and 51% (IXE Q2W); 36% and 51% (ADA/IXE); 19% and 47% (PBO/IXE). Corresponding ASAS40 response rates in COAST-W were 25% and 34% (IXE Q4W); 31% and 31% (IXE Q2W); 14% and 39% (PBO/IXE). Both ixekizumab regimens sustained improvements in disease activity, physical function, objective markers of inflammation, QoL, health status and overall function up to 52 weeks. Safety through 52 weeks of ixekizumab was consistent with safety through 16 weeks. CONCLUSION:The significant efficacy demonstrated with ixekizumab at week 16 was sustained for up to 52 weeks in bDMARD-naive and TNFi-experienced patients. bDMARD-naive patients initially treated with ADA demonstrated further numerical improvements after switching to ixekizumab. Safety findings were consistent with the known safety profile of ixekizumab. TRIAL REGISTRATION NUMBER:NCT02696785/NCT02696798.
- Published
- 2020
14. A latent class based imputation method under Bayesian quantile regression framework using asymmetric Laplace distribution for longitudinal medication usage data with intermittent missing values
- Author
-
Lee, Minjae, Rahbar, Mohammad H, Gensler, Lianne S, Brown, Matthew, Weisman, Michael, and Reveille, John D
- Subjects
Mathematical Sciences ,Statistics ,Clinical Research ,Generic health relevance ,Anti-Inflammatory Agents ,Non-Steroidal ,Bayes Theorem ,Data Interpretation ,Statistical ,Drug Therapy ,Humans ,Longitudinal Studies ,Research Design ,Spondylitis ,Ankylosing ,Time Factors ,Treatment Outcome ,Multiple imputation ,intermittent missing ,Bayesian quantile regression ,latent class ,asymmetric Laplace distribution ,prospective study of outcomes in ankylosing spondylitis ,Pharmacology and Pharmaceutical Sciences ,Statistics & Probability ,Pharmacology and pharmaceutical sciences - Abstract
Evaluating the association between diseases and the longitudinal pattern of pharmacological therapy has become increasingly important. However, in many longitudinal studies, self-reported medication usage data collected at patients' follow-up visits could be missing for various reasons. These pieces of missing or inaccurate/untenable information complicate determining the trajectory of medication use and its complete effects for patients. Although longitudinal models can deal with specific types of missing data, inappropriate handling of this issue can lead to a biased estimation of regression parameters especially when missing data mechanisms are complex and depend upon multiple sources of variation. We propose a latent class-based multiple imputation (MI) approach using a Bayesian quantile regression (BQR) that incorporates cluster of unobserved heterogeneity for medication usage data with intermittent missing values. Findings from our simulation study indicate that the proposed method performs better than traditional MI methods under certain scenarios of data distribution. We also demonstrate applications of the proposed method to data from the Prospective Study of Outcomes in Ankylosing Spondylitis (AS) cohort when assessing an association between longitudinal nonsteroidal anti-inflammatory drugs (NSAIDs) usage and radiographic damage in AS, while the longitudinal NSAID index data are intermittently missing.
- Published
- 2020
15. Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap
- Author
-
Deodhar, Atul, Gensler, Lianne S, Magrey, Marina, Walsh, Jessica A, Winseck, Adam, Grant, Daniel, and Mease, Philip J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Chronic Pain ,Sleep Research ,Behavioral and Social Science ,Pain Research ,Clinical Research ,Actigraphy ,Ankylosing spondylitis ,Axial spondyloarthritis ,Fatigue ,Physical activity ,Polysomnography ,Radiographic axial spondyloarthritis ,Rheumatology ,Sleep disturbance - Abstract
Patients with axial spondyloarthritis (axSpA) frequently report pain, stiffness, fatigue, and sleep problems, which may lead to impaired physical activity. The majority of reported-on measures evaluating physical activity and sleep disturbance in axSpA are self-reported questionnaires, which can be impacted by patient recall (reporting bias). One objective measure, polysomnography, has been employed to evaluate sleep in patients with axSpA; however, it is an intrusive measure and cannot be used over the long term. More convenient objective measures are therefore needed to allow for the long-term assessment of both sleep and physical activity in patients' daily lives. Wearable technology that utilizes actigraphy is increasingly being used for the objective measurement of physical activity and sleep in various therapy areas, as it is unintrusive and suitable for continuous tracking to allow longitudinal assessment. Actigraphy characterizes sleep disruption as restless movement while sleeping, which is particularly useful when studying conditions such as axSpA in which chronic pain and discomfort due to stiffness may be evident. Studies have also shown that actigraphy can effectively assess the impact of disease on physical activity. More research is needed to establish the usefulness of objective monitoring of sleep and physical activity specifically in axSpA patients over time. This review summarizes the current perspectives on physical activity and sleep quality in patients with axSpA, and the possible role of actigraphy in the future to more accurately evaluate the impact of treatment interventions on sleep and physical activity in axSpA.Funding: Novartis Pharmaceuticals Corporation.Plain Language Summary: Plain language summary available for this article.
- Published
- 2019
16. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts
- Author
-
Boel, Anne, Molto, Anna, van der Heijde, Désirée, Ciurea, Adrian, Dougados, Maxime, Gensler, Lianne S, Santos, Maria-José, De Miguel, Eugenio, Poddubnyy, Denis, Rudwaleit, Martin, van Tubergen, Astrid, van Gaalen, Floris A, and Ramiro, Sofia
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Pain Research ,Adult ,Cohort Studies ,Female ,Humans ,Male ,Middle Aged ,Radiography ,Rheumatology ,Sacroiliitis ,Spondylarthritis ,Spondylitis ,Ankylosing ,ankylosing spondylitis ,epidemiology ,outcomes research ,spondyloarthritis ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
BackgroundPatients with spondyloarthritis with radiographic sacroiliitis are traditionally classified according to the modified New York (mNY) criteria as ankylosing spondylitis (AS) and more recently according to the Assessment of SpondyloArthritis international Society (ASAS) criteria as radiographic axial spondyloarthritis (r-axSpA).ObjectiveTo investigate the agreement between the mNY criteria for AS and the ASAS criteria for r-axSpA and reasons for disagreement.MethodsPatients with back pain ≥3 months diagnosed as axSpA with radiographic sacroiliitis (mNY radiographic criterion) were selected from eight cohorts (ASAS, Esperanza, GESPIC, OASIS, Reuma.pt, SCQM, SPACE, UCSF). Subsequently, we calculated the percentage of patients who fulfilled the ASAS r-axSpA criteria within the group of patients who fulfilled the mNY criteria and vice versa in six cohorts with complete information.ResultsOf the 3882 patients fulfilling the mNY criteria, 93% also fulfilled the ASAS r-axSpA criteria. Inversely, of the 3434 patients fulfilling the ASAS r-axSpA criteria, 96% also fulfilled the mNY criteria. The main cause for discrepancy between the two criteria sets was the reported age at onset of back pain.ConclusionAlmost all patients with axSpA with radiographic sacroiliitis fulfil both ASAS and mNY criteria, which supports the interchangeable use of the terms AS and r-axSpA.
- Published
- 2019
17. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
- Author
-
Ward, Michael M, Deodhar, Atul, Gensler, Lianne S, Dubreuil, Maureen, Yu, David, Khan, Muhammad Asim, Haroon, Nigil, Borenstein, David, Wang, Runsheng, Biehl, Ann, Fang, Meika A, Louie, Grant, Majithia, Vikas, Ng, Bernard, Bigham, Rosemary, Pianin, Michael, Shah, Amit Aakash, Sullivan, Nancy, Turgunbaev, Marat, Oristaglio, Jeff, Turner, Amy, Maksymowych, Walter P, and Caplan, Liron
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Arthritis ,Rare Diseases ,Autoimmune Disease ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Inflammatory and immune system ,Good Health and Well Being ,Anti-Inflammatory Agents ,Non-Steroidal ,Antibodies ,Monoclonal ,Humanized ,Antirheumatic Agents ,Biological Products ,Biosimilar Pharmaceuticals ,Deprescriptions ,Humans ,Magnetic Resonance Imaging ,Piperidines ,Protein Kinase Inhibitors ,Pyrimidines ,Pyrroles ,Radiography ,Societies ,Medical ,Spondylarthropathies ,Spondylitis ,Ankylosing ,Tumor Necrosis Factor Inhibitors ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectiveTo update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA).MethodsWe conducted updated systematic literature reviews for 20 clinical questions on pharmacologic treatment addressed in the 2015 guidelines, and for 26 new questions on pharmacologic treatment, treat-to-target strategy, and use of imaging. New questions addressed the use of secukinumab, ixekizumab, tofacitinib, tumor necrosis factor inhibitor (TNFi) biosimilars, and biologic tapering/discontinuation, among others. We used the Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations and required at least 70% agreement among the voting panel.ResultsRecommendations for AS and nonradiographic axial SpA are similar. TNFi are recommended over secukinumab or ixekizumab as the first biologic to be used. Secukinumab or ixekizumab is recommended over the use of a second TNFi in patients with primary nonresponse to the first TNFi. TNFi, secukinumab, and ixekizumab are favored over tofacitinib. Co-administration of low-dose methotrexate with TNFi is not recommended, nor is a strict treat-to-target strategy or discontinuation or tapering of biologics in patients with stable disease. Sulfasalazine is recommended only for persistent peripheral arthritis when TNFi are contraindicated. For patients with unclear disease activity, spine or pelvis magnetic resonance imaging could aid assessment. Routine monitoring of radiographic changes with serial spine radiographs is not recommended.ConclusionThese recommendations provide updated guidance regarding use of new medications and imaging of the axial skeleton in the management of AS and nonradiographic axial SpA.
- Published
- 2019
18. COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis
- Author
-
Deodhar, Atul, Bhana, Suleman, Winthrop, Kevin, and Gensler, Lianne S.
- Published
- 2022
- Full Text
- View/download PDF
19. Virtually Speaking: The Impact of a Nationwide Synchronous and Asynchronous Learning Forum
- Author
-
Dua, Anisha B., Bolster, Marcy B., Gensler, Lianne S., Kolfenbach, Jason, Mamut, Mary H., Seo, Philip, and Jonas, Beth L.
- Published
- 2023
- Full Text
- View/download PDF
20. A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
- Author
-
Deodhar, Atul, Gensler, Lianne S, Kay, Jonathan, Maksymowych, Walter P, Haroon, Nigil, Landewé, Robert, Rudwaleit, Martin, Hall, Stephen, Bauer, Lars, Hoepken, Bengt, Peyrecave, Natasha, Kilgallen, Brian, and Heijde, Désirée
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Clinical Trials and Supportive Activities ,Arthritis ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adult ,C-Reactive Protein ,Certolizumab Pegol ,Double-Blind Method ,Female ,Humans ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Sacroiliitis ,Spondylarthropathies ,Treatment Outcome ,Tumor Necrosis Factor Inhibitors ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectiveThe natural history of nonradiographic axial spondyloarthritis (SpA) is incompletely characterized, and there are concerns that nonsteroidal antiinflammatory drugs provide inadequate disease control in patients with active disease. This study was undertaken to investigate the effects of certolizumab pegol (CZP), an anti-tumor necrosis factor treatment, in patients with nonradiographic axial SpA with objective signs of inflammation.MethodsIn this ongoing parallel-group double-blind study, adults with active disease were recruited from 80 centers in Australia, Europe, North America, and Taiwan, and were randomized 1:1 to receive placebo or CZP (400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks) in addition to nonbiologic background medication (NBBM). Switching to open-label CZP (or other biologic) or making background medication changes was permitted at any point during the trial, although changes before week 12 were discouraged. The primary end point was the proportion of patients achieving major improvement (MI) (i.e., a ≥2.0-point decrease in the score from baseline or achievement of the lowest possible score [0.6]) in the Ankylosing Spondylitis Disease Activity Score (ASDAS) at week 52.ResultsA total of 317 patients were randomized to receive placebo plus NBBM (n = 158) or CZP plus NBBM (n = 159). ASDAS-MI at week 52 was achieved in 47.2% (75 of 159) of CZP plus NBBM patients, which was significantly greater (P < 0.0001) than the 7.0% (11 of 158) of placebo plus NBBM patients in whom ASDAS-MI was achieved. Of the placebo plus NBBM patients, 60.8% (96 of 158) switched to open-label treatment before week 52 compared to 12.6% (20 of 159) of the CZP plus NBBM patients.ConclusionAdding CZP to background medication is superior to adding placebo in patients with active nonradiographic axial SpA. These results indicate that remission in nonradiographic axial SpA treated without biologics occurs infrequently, demonstrating the need for treatment beyond nonbiologic therapy.
- Published
- 2019
21. Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
- Author
-
Ghosh, Subrata, Gensler, Lianne S, Yang, Zijiang, Gasink, Chris, Chakravarty, Soumya D, Farahi, Kamyar, Ramachandran, Paraneedharan, Ott, Elyssa, and Strober, Bruce E
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Inflammatory and immune system ,Pharmacology and Pharmaceutical Sciences ,Pharmacology & Pharmacy ,Pharmacology and pharmaceutical sciences - Abstract
In the original publication of this article, the following correction should be noted in Table 5.
- Published
- 2019
22. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
- Author
-
Ghosh, Subrata, Gensler, Lianne S, Yang, Zijiang, Gasink, Chris, Chakravarty, Soumya D, Farahi, Kamyar, Ramachandran, Paraneedharan, Ott, Elyssa, and Strober, Bruce E
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Autoimmune Disease ,Psoriasis ,Rare Diseases ,Arthritis ,Clinical Research ,Clinical Trials and Supportive Activities ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Inflammatory and immune system ,Adult ,Antibodies ,Monoclonal ,Arthritis ,Psoriatic ,Crohn Disease ,Female ,Humans ,Male ,Methotrexate ,Middle Aged ,Severity of Illness Index ,Treatment Outcome ,Ustekinumab ,Pharmacology and Pharmaceutical Sciences ,Pharmacology & Pharmacy ,Pharmacology and pharmaceutical sciences - Abstract
IntroductionTheoretical risks of biologic agents remain under study.ObjectiveThe aim of this study was to integrate 1-year safety data from 12 ustekinumab registrational trials.MethodsPatients had moderate-to-severe plaque psoriasis, active psoriatic arthritis (PsA) (± methotrexate), or moderate-to-severe Crohn's disease (CD; failed/intolerant of immunomodulators/corticosteroids). Psoriatic patients received subcutaneous ustekinumab 45/90 mg or placebo, generally at week 0, week 4, then every 12 weeks thereafter, while those with CD received a single intravenous ustekinumab dose (130 mg or weight range-based dosing of approximately 6 mg/kg) or placebo induction dose at week 0, followed by subcutaneous ustekinumab 90 mg at week 8 and every 8/12 weeks thereafter. The incidence rates of a priori-defined safety events were integrated post hoc (adjusted for duration of follow-up, reported per 100 patient-years [PYs]).ResultsAmong 6280 enrolled patients, 5884 ustekinumab-treated patients (psoriasis: 3117; PsA: 1018; CD: 1749) contributed 4521 PYs versus 674 PYs in placebo-treated patients through year 1 (829 PYs and 385 PYs during 8- to 16-week controlled periods). Combined across diseases among ustekinumab- versus placebo-treated patients, respective incidences/100 PYs (95% confidence intervals) of infections were 125.4 (122.2-128.7) versus 129.4 (120.9-138.3) through year 1, and not meaningfully increased in patients who did versus those who did not receive methotrexate (92.5 [84.2-101.5] vs. 115.3 [109.9-121.0]), or significantly increased in patients who did versus those who did not receive corticosteroids (116.3 [107.3-125.9] vs. 107.3 [102.0-112.8]) at baseline. Major adverse cardiovascular events (0.5 [0.3-0.7] vs. 0.3 [0.0-1.1]), malignancies (0.4 [0.2-0.6] vs. 0.2 [0.0-0.8]), and deaths (0.1 [0.0-0.3] vs. 0.0 [0.0-0.4]) were rare across indications.ConclusionsUstekinumab demonstrated a favorable and consistent safety profile across registrational trials in approved indications.Trial registrationsClinicalTrials.gov identifier: NCT00320216, NCT00267969, NCT00307437, NCT00454584, NCT00267956, NCT01009086, NCT01077362, NCT00265122, NCT00771667, NCT01369329, NCT01369342, and NCT01369355.
- Published
- 2019
23. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.
- Author
-
Deodhar, Atul, Gensler, Lianne S, Sieper, Joachim, Clark, Michael, Calderon, Cesar, Wang, Yuhua, Zhou, Yiying, Leu, Jocelyn H, Campbell, Kim, Sweet, Kristen, Harrison, Diane D, Hsia, Elizabeth C, and van der Heijde, Désirée
- Subjects
Humans ,Spondylarthropathies ,Spondylitis ,Ankylosing ,Antirheumatic Agents ,Antibodies ,Monoclonal ,Treatment Outcome ,Double-Blind Method ,Adult ,Middle Aged ,Female ,Male ,Ustekinumab ,Injection Site Reaction ,Spondylitis ,Ankylosing ,Antibodies ,Monoclonal - Abstract
ObjectiveTo evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo-controlled studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included patients with radiographic axial SpA (anti-tumor necrosis factor [anti-TNF]-naive patients and patients with inadequate response or intolerance to anti-TNF, respectively); study 3 patients had nonradiographic axial SpA.MethodsIn all 3 studies, patients were randomly assigned (1:1:1) to receive subcutaneous ustekinumab at 45 mg or 90 mg or placebo up to 24 weeks, after which placebo-treated patients were rerandomized to receive ustekinumab at 45 mg or 90 mg. The primary end point in studies 1 and 2 was the proportion of patients who met the Assessment of SpondyloArthritis international Society criteria for 40% improvement in disease activity (achieved an ASAS40 response). The primary end point in study 3 was the proportion of patients who achieved an ASAS20 response. Other disease activity and safety measures were also evaluated. A week 24 analysis of study 1 was preplanned to determine continuation of studies 2 and 3.ResultsFor study 1, the primary and major secondary end points were not met, and the study was discontinued. As a result, studies 2 and 3 were prematurely discontinued before they were fully enrolled. For all 3 studies, neither ustekinumab dose group demonstrated clinically meaningful improvement over placebo on key efficacy end points. The proportion of patients experiencing adverse events in the ustekinumab groups was consistent with that in previous studies.ConclusionIn these 3 placebo-controlled trials, efficacy of ustekinumab in the treatment of axial SpA was not demonstrated. The safety profile was consistent with that of studies in other indications.
- Published
- 2019
24. HLA class I and II alleles in susceptibility to ankylosing spondylitis
- Author
-
Reveille, John D, Zhou, Xiaodong, Lee, MinJae, Weisman, Michael H, Yi, Lin, Gensler, Lianne S, Zou, Hejian, Ward, Michael M, Ishimori, Mariko L, Learch, Thomas J, He, Dongyi, Rahbar, Mohammad H, Wang, Jiucun, and Brown, Matthew A
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Arthritis ,Genetics ,Clinical Research ,Autoimmune Disease ,Aetiology ,2.1 Biological and endogenous factors ,Adult ,Alleles ,Asian People ,Black People ,Female ,Genetic Predisposition to Disease ,Histocompatibility Antigens Class I ,Histocompatibility Antigens Class II ,Humans ,Male ,Racial Groups ,Spondylitis ,Ankylosing ,White People ,African-American ,Chinese ,HLA ,disease susceptibility ,ethnicity ,spondylitis ,uveitis ,Clinical Sciences ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectiveTo examine associations of HLA class I and class II alleles with ankylosing spondylitis (AS) in three cohorts of patients of European, Asian and African ancestry.MethodsHLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1 and HLA-DPB1 alleles were genotyped in 1948 unrelated white and 67 African-American patients with AS from the Prospective Study of Outcomes in Ankylosing Spondylitis cohort, the North American Spondylitis Consortium and Australo-Anglo-American Spondyloarthritis Consortium, 990 white and 245 African-American Controls and HLA-B alleles in 442 Han Chinese patients with AS and 346 controls from Shanghai and Gansu, China. In addition to the case:control analyses, HLA-B*27-negative patients with AS were analysed separately, and logistic regression and 'relative predispositional effects' (RPE) analyses were carried out to control for the major effect of HLA-B*27 on disease susceptibility.ResultsAlthough numerous associations were seen between HLA alleles and AS in whites, among HLA-B*27-negative patients with AS , positive associations were seen with HLA-A*29, B*38, B*49, B*52, DRB1*11 and DPB1*03:01 and negative associations with HLA-B*07, HLA-B*57, HLA-DRB1*15:01, HLA-DQB1*02:01 and HLA-DQB1*06:02. Additional associations with HLA-B*14 and B*40 (B60) were observed via RPE analysis, which excludes the HLA-B*27 alleles. The increased frequency of HLA-B*40:01 and decreased frequency of HLA-B*07 was also seen in Han Chinese and African-Americans with AS. HLA-B*08 was decreased in whites with acute anterior uveitis.ConclusionsThese data, analysing the largest number of patients with AS examined to date in three ethnic groups, confirm that other HLA class I and II alleles other than HLA-B*27 to be operative in AS predisposition.
- Published
- 2019
25. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
- Author
-
van der Heijde, Désirée, Baraliakos, Xenofon, Gensler, Lianne S, Maksymowych, Walter P, Tseluyko, Vira, Nadashkevich, Oleg, Abi-Saab, Walid, Tasset, Chantal, Meuleners, Luc, Besuyen, Robin, Hendrikx, Thijs, Mozaffarian, Neelufar, Liu, Ke, Greer, Joy M, Deodhar, Atul, and Landewé, Robert
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Arthritis ,Clinical Research ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adult ,Antirheumatic Agents ,Double-Blind Method ,Female ,Humans ,Janus Kinase 1 ,Janus Kinase Inhibitors ,Male ,Middle Aged ,Nasopharyngitis ,Opportunistic Infections ,Pneumonia ,Pyridines ,Severity of Illness Index ,Spondylitis ,Ankylosing ,Treatment Outcome ,Triazoles ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundAt present, biological disease-modifying anti-rheumatic drugs (DMARDs) are the only treatment recommended for patients with ankylosing spondylitis who have not responded to first-line treatment with non-steroidal anti-inflammatory drugs (NSAIDs). The TORTUGA trial investigated the efficacy and safety of filgotinib, an oral selective Janus kinase 1 (JAK1) inhibitor, for the treatment of patients with active ankylosing spondylitis.MethodsIn this completed, randomised, double-blind, placebo-controlled, phase 2 trial, we enrolled adult patients from 30 sites in seven countries (Belgium, Bulgaria, Czech Republic, Estonia, Poland, Spain, and Ukraine). Eligible patients had active ankylosing spondylitis and an inadequate response or intolerance to two or more NSAIDs. Patients were randomly assigned (1:1) with an interactive web-based response system to receive filgotinib 200 mg or placebo orally once daily for 12 weeks. Randomisation was stratified by current use of conventional synthetic DMARDs and previous receipt of anti-tumour necrosis factor therapy. The patients, study team, and study sponsor were masked to treatment assignment. The primary endpoint was the change from baseline in ankylosing spondylitis disease activity score (ASDAS) at week 12, which was assessed in the full analysis set (ie, all randomised patients who received at least one dose of study drug). Safety was assessed according to actual treatment received. This trial is registered with ClinicalTrials.gov, number NCT03117270.FindingsBetween March 7, 2017, and July 2, 2018, 263 patients were screened and 116 randomly assigned to filgotinib (n=58) or placebo (n=58). 55 (95%) patients in the filgotinib group and 52 (90%) in the placebo group completed the study; three (5%) patients in the filgotinib group and six (10%) in the placebo group discontinued treatment. The mean ASDAS change from baseline to week 12 was -1·47 (SD 1·04) in the filgotinib group and -0·57 (0·82) in the placebo group, with a least squares mean difference between groups of -0·85 (95% CI -1·17 to -0·53; p
- Published
- 2018
26. Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials.
- Author
-
Deodhar, Atul, Baraliakos, Xenofon, Magrey, Marina, Gensler, Lianne S., Thorat, Amit V., Pemmaraju, Surya Kiran, Cadatal, Mary Jane, and Nash, Peter
- Published
- 2024
- Full Text
- View/download PDF
27. Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head‐to‐Head Randomized Phase IIIb Study.
- Author
-
Baraliakos, Xenofon, Østergaard, Mikkel, Poddubnyy, Denis, van der Heijde, Désirée, Deodhar, Atul, Machado, Pedro M., Navarro‐Compán, Victoria, Hermann, Kay Geert A., Kishimoto, Mitsumasa, Lee, Eun Young, Gensler, Lianne S., Kiltz, Uta, Eigenmann, Marco F., Pertel, Patricia, Readie, Aimee, Richards, Hanno B., Porter, Brian, and Braun, Juergen
- Subjects
COMBINATION drug therapy ,ANTI-inflammatory agents ,RESEARCH funding ,PATIENT safety ,ANKYLOSIS ,EDEMA ,LOGISTIC regression analysis ,QUESTIONNAIRES ,DESCRIPTIVE statistics ,MAGNETIC resonance imaging ,ANALYSIS of covariance ,CHI-squared test ,MONOCLONAL antibodies ,ADALIMUMAB ,DRUG efficacy ,INTRACLASS correlation ,BIOSIMILARS ,SPONDYLOARTHROPATHIES ,HEALTH outcome assessment ,CONFIDENCE intervals ,DATA analysis software ,DISEASE progression ,INTERLEUKINS ,C-reactive protein ,DRUG tolerance ,SUBCUTANEOUS injections ,DRUG dosage ,DRUG administration ,CHEMICAL inhibitors - Abstract
Objective: Spinal radiographic progression is an important outcome in radiographic axial spondyloarthritis (SpA). The objective of the phase IIIb SURPASS study was to compare spinal radiographic progression in patients with radiographic axial SpA treated with secukinumab (interleukin‐17A inhibitor) versus adalimumab biosimilar (Sandoz adalimumab [SDZ‐ADL]; tumor necrosis factor inhibitor). Methods: Biologic‐naive patients with active radiographic axial SpA, at high risk of radiographic progression (high‐sensitivity C‐reactive protein [hsCRP] ≥5 mg/L and/or ≥1 syndesmophyte[s] on spinal radiographs), were randomized (1:1:1) to secukinumab (150/300 mg) or SDZ‐ADL (40 mg). The proportion of patients with no radiographic progression (change from baseline [CFB] in modified Stoke Ankylosing Spondylitis Spinal Score [mSASSS] ≤0.5) on secukinumab versus SDZ‐ADL at week 104 (primary endpoint), mean CFB‐mSASSS, proportion of patients with ≥1 syndesmophyte(s) at baseline with no new syndesmophyte(s), and safety were evaluated. Results: Overall, 859 patients (78.5% male, mSASSS 16.6, Bath Ankylosing Spondylitis Disease Activity Index 7.1, hsCRP 20.4 mg/L, and 73.0% with ≥1 syndesmophyte[s]) received secukinumab 150 mg (n = 287), secukinumab 300 mg (n = 286), or SDZ‐ADL (n = 286). At week 104, the proportion of patients with no radiographic progression was 66.1%, 66.9%, and 65.6% (P = not significant, both secukinumab doses) and mean CFB‐mSASSS was 0.54, 0.55, and 0.72 in secukinumab 150 mg, secukinumab 300 mg, and SDZ‐ADL arms, respectively. Overall, 56.9%, 53.8%, and 53.3% of patients on secukinumab 150 mg, secukinumab 300 mg, and SDZ‐ADL, respectively, with ≥1 syndesmophyte(s) at baseline did not develop new syndesmophyte(s) by week 104. There were no unexpected safety findings. Conclusion: Spinal radiographic progression over two years was low with no significant difference between secukinumab and SDZ‐ADL arms. The safety of both treatments was consistent with previous reports. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohort
- Author
-
Dau, Jonathan D, Lee, MinJae, Ward, Michael M, Gensler, Lianne S, Brown, Matthew A, Learch, Thomas J, Diekman, Laura A, Tahanan, Amirali, Rahbar, Mohammad H, Weisman, Michael H, and Reveille, John D
- Subjects
Pharmacology and Pharmaceutical Sciences ,Biomedical and Clinical Sciences ,Clinical Sciences ,Depression ,Pain Research ,Clinical Research ,Mental Health ,Chronic Pain ,Musculoskeletal ,Adult ,Aged ,Analgesics ,Opioid ,Blood Sedimentation ,C-Reactive Protein ,Chi-Square Distribution ,Disability Evaluation ,Female ,Follow-Up Studies ,Humans ,Logistic Models ,Longitudinal Studies ,Male ,Middle Aged ,Multivariate Analysis ,Prospective Studies ,Risk Factors ,Self Report ,Severity of Illness Index ,Spondylitis ,Ankylosing ,Statistics ,Nonparametric ,Treatment Outcome ,PAIN ,COHORT STUDIES ,OPIOID ,ANKYLOSING SPONDYLITIS ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
OBJECTIVE:Opioid analgesics may be prescribed to ankylosing spondylitis (AS) patients with pain that is unresponsive to antirheumatic treatment. Our study assessed factors associated with opioid usage in AS. METHODS:A prospective cohort of 706 patients with AS meeting modified New York criteria followed at least 2 years underwent comprehensive clinical evaluation of disease activity and functional impairment. These were assessed by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI). Radiographic severity was assessed by the Bath Ankylosing Spondylitis Radiology Index and modified Stokes Ankylosing Spondylitis Scoring System. Medications taken concurrently with opioids, as well as C-reactive protein (CRP) levels and erythrocyte sedimentation rate (ESR), were determined at each study visit, performed every 6 months. Analyses were carried out at baseline, and longitudinal multivariable models were developed to identify factors independently associated with chronic and intermittent opioid usage over time. RESULTS:Factors significantly associated with opioid usage, especially chronic opioid use, included longer disease duration, smoking, lack of exercise, higher disease activity (BASDAI) and functional impairment (BASFI), depression, radiographic severity, and cardiovascular disease. Patients taking opioids were more likely to be using anxiolytic, hypnotic, antidepressant, and muscle relaxant medications. Multivariable analysis underscored the association with smoking, older age, antitumor necrosis factor agent use, and psychoactive drugs, as well as with subjective but not objective determinants of disease activity. CONCLUSION:Opioid usage was more likely to be associated with subjective measures (depression, BASDAI, BASFI) than objective measures (CRP, ESR), suggesting that pain in AS may derive from sources other than spinal inflammation alone.
- Published
- 2018
29. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
- Author
-
Smolen, Josef S, Schöls, Monika, Braun, Jürgen, Dougados, Maxime, FitzGerald, Oliver, Gladman, Dafna D, Kavanaugh, Arthur, Landewé, Robert, Mease, Philip, Sieper, Joachim, Stamm, Tanja, Wit, Maarten de, Aletaha, Daniel, Baraliakos, Xenofon, Betteridge, Neil, Bosch, Filip van den, Coates, Laura C, Emery, Paul, Gensler, Lianne S, Gossec, Laure, Helliwell, Philip, Jongkees, Merryn, Kvien, Tore K, Inman, Robert D, McInnes, Iain B, Maccarone, Mara, Machado, Pedro M, Molto, Anna, Ogdie, Alexis, Poddubnyy, Denis, Ritchlin, Christopher, Rudwaleit, Martin, Tanew, Adrian, Thio, Bing, Veale, Douglas, Vlam, Kurt de, and van der Heijde, Désirée
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Arthritis ,Autoimmune Disease ,Clinical Research ,Rare Diseases ,Inflammatory and immune system ,Advisory Committees ,Arthritis ,Psoriatic ,Axis ,Cervical Vertebra ,Consensus ,Decision Making ,Humans ,Severity of Illness Index ,Spondylitis ,Ankylosing ,Ankylosing Spondylitis ,Outcomes Research ,Psoriatic Arthritis ,Spondyloarthritis ,Treatment ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field.
- Published
- 2018
30. Successful treatment of mucous membrane pemphigoid with bortezomib.
- Author
-
Saeed, Lina, Schmidt, Timothy H, Gensler, Lianne S, Gross, Andrew J, Fox, Lindy P, Scharschmidt, Tiffany C, Gaensler, Karin, Naik, Haley, Rosenblum, Michael A, and Shinkai, Kanade
- Subjects
BP ,bullous pemphigoid ,MMP ,mucous membrane pemphigoid ,autoimmune blistering disease ,bortezomib ,mucous membrane pemphigoid - Published
- 2018
31. Ochronotic Arthropathy
- Author
-
Jafri, Kashif, Gensler, Lianne S, and Link, Thomas M
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Immunology ,Alkaptonuria ,Back Pain ,Diagnosis ,Differential ,Female ,Humans ,Joint Diseases ,Medical Illustration ,Middle Aged ,Ochronosis ,Radiography ,Spine ,Spondylitis ,Ankylosing ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Published
- 2017
32. Clinical Images: Ochronotic arthropathy.
- Author
-
Jafri, Kashif, Gensler, Lianne S, and Link, Thomas M
- Subjects
Spine ,Humans ,Spondylitis ,Ankylosing ,Joint Diseases ,Back Pain ,Alkaptonuria ,Ochronosis ,Diagnosis ,Differential ,Radiography ,Medical Illustration ,Middle Aged ,Female ,Spondylitis ,Ankylosing ,Diagnosis ,Differential - Published
- 2017
33. Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups
- Author
-
Jamalyaria, Farokh, Ward, Michael M, Assassi, Shervin, Learch, Thomas J, Lee, MinJae, Gensler, Lianne S, Brown, Matthew A, Diekman, Laura, Tahanan, Amirali, Rahbar, Mohammad H, Weisman, Michael H, and Reveille, John D
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Autoimmune Disease ,Arthritis ,Adult ,Black or African American ,Black People ,Blood Sedimentation ,Cross-Sectional Studies ,Disease Progression ,Female ,HLA-B27 Antigen ,Hispanic or Latino ,Humans ,Longitudinal Studies ,Male ,Middle Aged ,Prospective Studies ,Reproducibility of Results ,Severity of Illness Index ,Spine ,Spondylitis ,Ankylosing ,White People ,Young Adult ,Ankylosing spondylitis ,Blacks ,Disease severity ,HLA-B27 ,Latinos ,Arthritis & Rheumatology ,Clinical sciences ,Immunology ,Allied health and rehabilitation science - Abstract
The purpose of this study is to compare disease severity in ankylosing spondylitis (AS) in three ethnic groups. We assessed 925 AS patients (57 Blacks, 805 Whites, 63 Latinos) enrolled in the longitudinal Prospective Study of Outcomes in AS (PSOAS) for functional impairment, disease activity, and radiographic severity. Comparisons of clinical characteristics and HLA-B27 frequency for each group were performed, in two multivariable regression models, we compared the baseline Bath Ankylosing Spondylitis Radiographic Index (BASRI) and modified Stokes Ankylosing Spondylitis Spine Score (mSASSS) by ethnicity, adjusting for covariates. Blacks had greater functional impairment (Bath Ankylosing Spondylitis Functional Index) (median 62.5 vs. 27.8 in Whites and 38.1 in Latinos; p
- Published
- 2017
34. Cervical Spinal Fracture and Other Diagnoses Associated With Mortality in Hospitalized Ankylosing Spondylitis Patients.
- Author
-
Wysham, Katherine D, Murray, Sara G, Hills, Nancy, Yelin, Edward, and Gensler, Lianne S
- Subjects
Cervical Vertebrae ,Humans ,Spondylitis ,Ankylosing ,Spinal Fractures ,Hospital Mortality ,Aged ,Middle Aged ,Inpatients ,Female ,Male ,Spondylitis ,Ankylosing ,Clinical Sciences ,Psychology ,Public Health and Health Services - Abstract
ObjectiveLittle data exist regarding mortality in ankylosing spondylitis (AS). We assessed diagnoses associated with in-hospital mortality in AS using a population-based inpatient data set.MethodsData were abstracted from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample between 2007 and 2011. We identified AS admissions using International Classification of Diseases, Ninth Revision, Clinical Modification code 720.0. In-hospital mortality was the primary outcome. Logistic regression was used to evaluate the association between top diagnoses and in-hospital mortality. We performed a secondary analysis from the same years in all patients (with and without AS) with cervical spine (C-spine) fracture to determine whether AS was an independent risk factor for mortality.ResultsBetween 2007 and 2011, we identified 12,484 admissions and 267 deaths in AS patients. C-spine fracture with spinal cord injury and sepsis had the highest odds of death, with odds ratios (ORs) of 13.43 (95% confidence interval [95% CI] 8.00-22.55, P
- Published
- 2017
35. Relationship Between Body Mass Index, Disease Activity, and Exercise in Ankylosing Spondylitis
- Author
-
Liew, Jean W., Gianfrancesco, Milena A., Heckbert, Susan R., and Gensler, Lianne S.
- Published
- 2022
- Full Text
- View/download PDF
36. Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
- Author
-
Baraliakos, Xenofon, Van den Bosch, Filip, Machado, Pedro M., Gensler, Lianne S., Marzo-Ortega, Helena, Sherif, Bintu, Quebe-Fehling, Erhard, Porter, Brian, Gaillez, Corine, and Deodhar, Atul
- Published
- 2021
- Full Text
- View/download PDF
37. Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.
- Author
-
Deodhar, Atul, Machado, Pedro M, Mørup, Michael, Taieb, Vanessa, Willems, Damon, Orme, Michelle, Pritchett, David, and Gensler, Lianne S
- Subjects
THERAPEUTIC use of monoclonal antibodies ,PATIENT safety ,RESEARCH funding ,ANKYLOSIS ,ANTIRHEUMATIC agents ,META-analysis ,TREATMENT effectiveness ,MONOCLONAL antibodies ,SYSTEMATIC reviews ,DRUG efficacy ,SPONDYLOARTHROPATHIES ,COMPARATIVE studies - Abstract
Objectives To compare the efficacy and safety of bimekizumab 160 mg every 4 weeks, a selective inhibitor of IL-17F and IL-17A, with those of biologic/targeted synthetic DMARDs (b/tsDMARDs) in non-radiographic axial SpA (nr-axSpA) and AS. Methods A systematic literature review identified randomized controlled trials until January 2023 for inclusion in Bayesian network meta-analyses (NMAs), including three b/tsDMARDs exposure networks: predominantly-naïve, naïve, and experienced. Outcomes were Assessment of SpondyloArthritis international Society (ASAS)20, ASAS40 and ASAS partial remission (PR) response rates at 12–16 weeks. A safety NMA investigated discontinuations due to any reason and serious adverse events at 12–16 weeks. Results The NMA included 36 trials. The predominantly-naïve network provided the most comprehensive results. In the predominantly-naïve nr-axSpA analysis, bimekizumab had significantly higher ASAS20 response rates vs secukinumab 150 mg [with loading dose (LD)/without LD], and comparable response rates vs other active comparators. In the predominantly-naïve AS analysis, bimekizumab had significantly higher ASAS40 response rates vs secukinumab 150 mg (without LD), significantly higher ASAS-PR response rates vs secukinumab 150 mg (with LD) and comparable response rates vs other active comparators. Bimekizumab demonstrated similar safety to that of other b/tsDMARDs. Conclusion Across ASAS outcomes, bimekizumab was comparable with most b/tsDMARDs, including ixekizumab, TNF inhibitors and upadacitinib, and achieved higher response rates vs secukinumab for some ASAS outcomes in predominantly b/tsDMARD-naïve nr-axSpA and AS patients at 12–16 weeks. In a pooled axSpA network, bimekizumab demonstrated comparable safety vs other b/tsDMARDs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies.
- Author
-
Dubreuil, Maureen, Navarro-Compán, Victoria, Boonen, Annelies, Gaffney, Karl, Gensler, Lianne S., de la Loge, Christine, Vaux, Thomas, Fleurinck, Carmen, Massow, Ute, Taieb, Vanessa, Mørup, Michael F., Deodhar, Atul, and Rudwaleit, Martin
- Published
- 2024
- Full Text
- View/download PDF
39. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
- Author
-
Ward, Michael M, Deodhar, Atul, Akl, Elie A, Lui, Andrew, Ermann, Joerg, Gensler, Lianne S, Smith, Judith A, Borenstein, David, Hiratzka, Jayme, Weiss, Pamela F, Inman, Robert D, Majithia, Vikas, Haroon, Nigil, Maksymowych, Walter P, Joyce, Janet, Clark, Bruce M, Colbert, Robert A, Figgie, Mark P, Hallegua, David S, Prete, Pamela E, Rosenbaum, James T, Stebulis, Judith A, Van Den Bosch, Filip, Yu, David TY, Miller, Amy S, Reveille, John D, and Caplan, Liron
- Subjects
Arthritis ,Digestive Diseases ,Autoimmune Disease ,Clinical Research ,Inflammatory and immune system ,Musculoskeletal ,Good Health and Well Being ,Anti-Inflammatory Agents ,Non-Steroidal ,Humans ,Patient Education as Topic ,Spondylitis ,Ankylosing ,Clinical Sciences ,Public Health and Health Services ,Psychology - Abstract
ObjectiveTo provide evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA).MethodsA core group led the development of the recommendations, starting with the treatment questions. A literature review group conducted systematic literature reviews of studies that addressed 57 specific treatment questions, based on searches conducted in OVID Medline (1946-2014), PubMed (1966-2014), and the Cochrane Library. We assessed the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. A separate voting group reviewed the evidence and voted on recommendations for each question using the GRADE framework.ResultsIn patients with active AS, the strong recommendations included use of nonsteroidal antiinflammatory drugs (NSAIDs), use of tumor necrosis factor inhibitors (TNFi) when activity persists despite NSAID treatment, not to use systemic glucocorticoids, use of physical therapy, and use of hip arthroplasty for patients with advanced hip arthritis. Among the conditional recommendations was that no particular TNFi was preferred except in patients with concomitant inflammatory bowel disease or recurrent iritis, in whom TNFi monoclonal antibodies should be used. In patients with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi. Other recommendations for patients with nonradiographic axial SpA were based on indirect evidence and were the same as for patients with AS.ConclusionThese recommendations provide guidance for the management of common clinical questions in AS and nonradiographic axial SpA. Additional research on optimal medication management over time, disease monitoring, and preventive care is needed to help establish best practices in these areas.
- Published
- 2016
40. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT
- Author
-
Braun, Jürgen, Blanco, Ricardo, Marzo-Ortega, Helena, Gensler, Lianne S., van den Bosch, Filip, Hall, Stephen, Kameda, Hideto, Poddubnyy, Denis, van de Sande, Marleen, Wiksten, Anna S., Porter, Brian O., Shete, Abhijit, Richards, Hanno B., Haemmerle, Sibylle, and Deodhar, Atul
- Published
- 2021
- Full Text
- View/download PDF
41. Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1
- Author
-
Braun, Jürgen, Buehring, Bjoern, Baraliakos, Xenofon, Gensler, Lianne S., Porter, Brian, Quebe-Fehling, Erhard, and Haemmerle, Sibylle
- Published
- 2021
- Full Text
- View/download PDF
42. MR distribution of active inflammatory and chronic structural sacroiliac joint changes in axial spondyloarthropathy: Challenging conventional wisdom
- Author
-
Motamedi, Daria, Patel, Rina, Devulapalli, Kavi K., Gensler, Lianne S., and Steinbach, Lynne
- Published
- 2019
- Full Text
- View/download PDF
43. Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE
- Author
-
Landewé, Robert, van der Heijde, Désirée, Dougados, Maxime, Baraliakos, Xenofon, Van den Bosch, Filip, Gaffney, Karl, Bauer, Lars, Hoepken, Bengt, de Peyrecave, Natasha, Thomas, Karen, and Gensler, Lianne S.
- Published
- 2020
- Full Text
- View/download PDF
44. The changing profile of ankylosing spondylitis in the biologic era
- Author
-
Reveille, John D., Lee, MinJae, Gensler, Lianne S., Ward, Michael M., Hwang, Mark C., Learch, Thomas J., Tahanan, Amirali, Diekman, Laura, Rahbar, Mohammad H., Ishimori, Mariko L., and Weisman, Michael H.
- Published
- 2020
- Full Text
- View/download PDF
45. Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort
- Author
-
Hwang, Mark C., Lee, Min Jae, Gensler, Lianne S., Ward, Michael M., Brown, Matthew A., Eisen, Seth, Learch, Thomas J., Tahanan, Amirali, Rahbar, Mohammad H., Ishimori, Mariko L., Weisman, Michael H., and Reveille, John D.
- Published
- 2020
- Full Text
- View/download PDF
46. Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis
- Author
-
Cortes, A, Maksymowych, WP, Wordsworth, BP, Inman, RD, Danoy, P, Rahman, P, Stone, MA, Corr, M, Gensler, Lianne S, Gladman, D, Morgan, A, Marzo-Ortega, H, Ward, MM, SPARCC, TASC, Learch, TJ, Reveille, JD, Brown, MA, and Weisman, MH
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Immunology ,Genetics ,2.1 Biological and endogenous factors ,Aetiology ,Musculoskeletal ,Adult ,Bone Resorption ,Cervical Vertebrae ,Cyclooxygenase 1 ,Exons ,Female ,Genetic Association Studies ,Genotype ,Haplotypes ,Humans ,Lumbar Vertebrae ,Male ,Middle Aged ,Osteogenesis ,Polymorphism ,Single Nucleotide ,Radiography ,Receptor Activator of Nuclear Factor-kappa B ,Severity of Illness Index ,Spondylitis ,Ankylosing ,SPARCC ,TASC ,Ankylosing spondylitis ,genetic association study ,x-ray ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectiveTo identify genetic associations with severity of radiographic damage in ankylosing spondylitis (AS).MethodWe studied 1537 AS cases of European descent; all fulfilled the modified New York Criteria. Radiographic severity was assessed from digitised lateral radiographs of the cervical and lumbar spine using the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). A two-phase genotyping design was used. In phase 1, 498 single nucleotide polymorphisms (SNPs) were genotyped in 688 cases; these were selected to capture >90% of the common haplotypic variation in the exons, exon-intron boundaries, and 5 kb flanking DNA in the 5' and 3' UTR of 74 genes involved in anabolic or catabolic bone pathways. In phase 2, 15 SNPs exhibiting p
- Published
- 2015
47. Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1.
- Author
-
Cortes, Adrian, Pulit, Sara L, Leo, Paul J, Pointon, Jenny J, Robinson, Philip C, Weisman, Michael H, Ward, Michael, Gensler, Lianne S, Zhou, Xiaodong, Garchon, Henri-Jean, Chiocchia, Gilles, Nossent, Johannes, Lie, Benedicte A, Førre, Øystein, Tuomilehto, Jaakko, Laiho, Kari, Bradbury, Linda A, Elewaut, Dirk, Burgos-Vargas, Ruben, Stebbings, Simon, Appleton, Louise, Farrah, Claire, Lau, Jonathan, Haroon, Nigil, Mulero, Juan, Blanco, Francisco J, Gonzalez-Gay, Miguel A, Lopez-Larrea, C, Bowness, Paul, Gaffney, Karl, Gaston, Hill, Gladman, Dafna D, Rahman, Proton, Maksymowych, Walter P, Crusius, J Bart A, van der Horst-Bruinsma, Irene E, Valle-Oñate, Raphael, Romero-Sánchez, Consuelo, Hansen, Inger Myrnes, Pimentel-Santos, Fernando M, Inman, Robert D, Martin, Javier, Breban, Maxime, Wordsworth, Bryan Paul, Reveille, John D, Evans, David M, de Bakker, Paul IW, and Brown, Matthew A
- Subjects
Humans ,Spondylitis ,Ankylosing ,Genetic Predisposition to Disease ,Aminopeptidases ,HLA-B27 Antigen ,Minor Histocompatibility Antigens ,Case-Control Studies ,Major Histocompatibility Complex ,Epistasis ,Genetic ,Polymorphism ,Single Nucleotide ,HLA-B40 Antigen ,Epistasis ,Genetic ,Polymorphism ,Single Nucleotide ,Spondylitis ,Ankylosing - Abstract
Ankylosing spondylitis (AS) is a common, highly heritable, inflammatory arthritis for which HLA-B*27 is the major genetic risk factor, although its role in the aetiology of AS remains elusive. To better understand the genetic basis of the MHC susceptibility loci, we genotyped 7,264 MHC SNPs in 22,647 AS cases and controls of European descent. We impute SNPs, classical HLA alleles and amino-acid residues within HLA proteins, and tested these for association to AS status. Here we show that in addition to effects due to HLA-B*27 alleles, several other HLA-B alleles also affect susceptibility. After controlling for the associated haplotypes in HLA-B, we observe independent associations with variants in the HLA-A, HLA-DPB1 and HLA-DRB1 loci. We also demonstrate that the ERAP1 SNP rs30187 association is not restricted only to carriers of HLA-B*27 but also found in HLA-B*40:01 carriers independently of HLA-B*27 genotype.
- Published
- 2015
48. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis
- Author
-
Poddubnyy, Denis and Gensler, Lianne S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Autoimmune Disease ,Clinical Research ,Arthritis ,Antirheumatic Agents ,Clinical Trials as Topic ,Humans ,Remission Induction ,Remission ,Spontaneous ,Spondylarthritis ,Spondylitis ,Ankylosing ,Ankylosing spondylitis ,Non-radiographic axial spondyloarthritis ,Peripheral spondyloarthritis ,Reactive arthritis ,Treatment ,Remission ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
In spondyloarthritis (SpA), spontaneous remission is best described in reactive arthritis, a form of peripheral SpA. Prior SpA observational studies suggested that a significant percentage of patients reached spontaneous remission; however, these patients were followed up under older, broader European Spondyloarthropathy Study Group (ESSG) criteria or were not defined by specific criteria. In general, they were mixed populations of peripheral and axial disease, and the subsets were not differentiated when assessing end points such as remission. There are limited data on the natural history of axial SpA, in part because of the evolution of the criteria with the more recently developed Assessment of SpondyloArthritis International Society (ASAS) criteria, including the designation of non-radiographic axial SpA and peripheral SpA. Clinical trials have been conducted with various remission end points including withdrawal of therapy to determine remission maintenance. The following review addresses the potential for remission in axial and peripheral SpA based on the data from both observational studies and clinical trials.
- Published
- 2014
49. New Population‐Based Reference Values for Spinal Mobility Measures Based on the 2009–2010 National Health and Nutrition Examination Survey
- Author
-
Assassi, Shervin, Weisman, Michael H, Lee, MinJae, Savage, Laurie, Diekman, Laura, Graham, Tiffany A, Rahbar, Mohammad H, Schall, Joan I, Gensler, Lianne S, Deodhar, Atul A, Clegg, Daniel O, Colbert, Robert A, and Reveille, John D
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Nutrition ,Obesity ,Adult ,Aged ,Body Mass Index ,Body Weight ,Female ,Humans ,Male ,Middle Aged ,Nutrition Surveys ,Range of Motion ,Articular ,Reference Values ,Spine ,Young Adult ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectiveTo report population-based percentile reference values for selected spinal mobility measures in a nationally representative sample of 5,001 US adults ages 20-69 years who were examined in the 2009-2010 US National Health and Nutrition Examination Survey (NHANES).MethodsOcciput-to-wall distance (OWD), thoracic expansion (TE), and anterior lumbar flexion (ALF; by modified Schober test) were measured by trained examiners in a standardized manner. TE was measured at the xiphisternal level, while the lower reference point for ALF was a line marked at the level of the superior margin of the lateral iliac crests. We report reference values based on the 95th percentile for the OWD and the 5th percentile for TE and ALF, as well as other summary statistics for these measures, in the study population.ResultsAn OWD of >0 was present in 3.8% of the participants, while 8.8% of them had out-of-range values for TE based on the commonly used threshold of 2.5 cm. The 95th percentile of the OWD measurement was 0, while the 5th percentile for TE and ALF were 1.9 cm and 2 cm, respectively. The spinal measures were significantly associated with sex, age, ethnicity, height, and body mass index (BMI). Exclusion of individuals with severe obesity (BMI >35 kg/m(2) ) changed the proposed reference values for TE and ALF to 2.2 cm and 1.9 cm, respectively.ConclusionWe verified a reference value of 0 for the OWD in the general population. Using the reported population-based percentile values, new reference values for TE and ALF can be derived.
- Published
- 2014
50. MICA, a gene contributing strong susceptibility to ankylosing spondylitis
- Author
-
Zhou, Xiaodong, Wang, Jiucun, Zou, Hejian, Ward, Michael M, Weisman, Michael H, Espitia, Maribel G, Xiao, Xiangjun, Petersdorf, Effie, Mignot, Emmanuel, Martin, Javier, Gensler, Lianne S, Scheet, Paul, and Reveille, John D
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Prevention ,Autoimmune Disease ,Human Genome ,Arthritis ,Genetics ,Aetiology ,2.1 Biological and endogenous factors ,Inflammatory and immune system ,Adult ,Asian ,Cohort Studies ,Female ,Genetic Markers ,Genetic Predisposition to Disease ,HLA-B Antigens ,Histocompatibility Antigens Class I ,Humans ,Linkage Disequilibrium ,Male ,Middle Aged ,Risk Factors ,Spondylitis ,Ankylosing ,United States ,White People ,Ankylosing Spondylitis ,Gene Polymorphism ,Inflammation ,Clinical Sciences ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectiveThe human major histocompatibility complex class I chain-related gene A (MICA) controls the immune process by balancing activities of natural killer cells, γδ T cells and αβ CD8 T cells, and immunosuppressive CD4 T cells. MICA is located near HLA-B on chromosome 6. Recent genomewide association studies indicate that genes most strongly linked to ankylosing spondylitis (AS) susceptibility come from the region containing HLA-B and MICA. While HLA-B27 is a well-known risk genetic marker for AS, the potential effect of linkage disequilibrium (LD) shields any associations of genes around HLA-B with AS. The aim of this study was to investigate a novel independent genetic association of MICA to AS.MethodsWe examined 1543 AS patients and 1539 controls from two ethnic populations by sequencing MICA and genotyping HLA-B alleles. Initially, 1070 AS patients and 1003 controls of European ancestry were used as a discovery cohort, followed by a confirmation cohort of 473 Han Chinese AS patients and 536 controls. We performed a stratified analysis based on HLA-B27 carrier status. We also conducted logistic regression with a formal interaction term.ResultsSequencing of MICA identified that MICA*007:01 is a significant risk allele for AS in both Caucasian and Han Chinese populations, and that MICA*019 is a major risk allele in Chinese AS patients. Conditional analysis of MICA alleles on HLA-B27 that unshielded LD effect confirmed associations of the MICA alleles with AS.ConclusionsParallel with HLA-B27, MICA confers strong susceptibility to AS in US white and Han Chinese populations.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.